Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.45 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.45 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27979205 | 0.89 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL17099404 | 0.88 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL151327 | 0.84 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL8579994 | 0.83 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL6515764 | 0.81 | SLC28A1 (0.38) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL30480815 | 0.80 | SLC28A1 (0.37) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL30974580 | 0.80 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL5075381 | 0.80 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL25425585 | 0.79 | SLC29A1 (0.39) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL27818952 | 0.79 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250383350-A1 | ANALYTE DETECTION USING APTAMERS | UNIV MICHIGAN REGENTS (US) | 2025-12-18 | — | — | US | disclosed |
| WO-2025096203-A1 | TARGETING A CHIMERIC RNA FOR TREATING CANCER | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-114404581-A | Cancer vaccine | 摩登纳特斯有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-113577019-A | Ready-to-fill gemcitabine solutions | 太阳医药工业有限公司 | 2021-11-02 | — | — | CN | disclosed |
| EP-2656848-B2 | Ready to be infused gemcitabine solution | SUN PHARMACEUTICAL IND LTD (IN) | 2018-09-19 | — | — | EP | disclosed |
| US-9241948-B2 | Ready to be infused gemcetabine solution | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2016-01-26 | — | — | US | disclosed |
| EP-2656848-B1 | Ready to be infused gemcitabine solution | SUN PHARMACEUTICAL IND LTD (IN) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013171763-A1 | READY TO BE INFUSED GEMCITABINE SOLUTION | SUN PHARMACEUTICAL INDUSTRIES LTD (IN) | 2013-11-21 | — | — | WO | disclosed |
| US-20130288994-A1 | READY TO BE INFUSED GEMCETABINE SOLUTION | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2013-10-31 | — | — | US | disclosed |
| EP-2656848-A1 | Ready to be infused gemcitabine solution | Sun Pharmaceutical Industries Limited (IN) | 2013-10-30 | — | — | EP | disclosed |
| EP-1480982-A4 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20040248844-A1 | Method for the treatment or prevention of Flavivirus infections using nucleoside analogues | ISMAILI HICHAM MOULAY ALAOUI (CA) | 2004-12-09 | — | — | US | disclosed |
| EP-1480982-A2 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | Pharmasset Ltd. (BB) | 2004-12-01 | — | — | EP | disclosed |
| US-6784161-B2 | VIRICIDES FOR HEPATITIS C | BIOCHEM PHARMA, INC. (CA) | 2004-08-31 | — | — | US | disclosed |
| WO-2003068162-A2 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET LTD. (BB) | 2003-08-21 | — | — | WO | disclosed |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | VIROCHEM PHARMA INC. (CA) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248844-A1 | Method for the treatment or prevention of Flavivirus infections using nucleoside analogues | NUDT1, HAVCR2, SLC28A1 | SLC28A1 3/4885SLC28A2 8/4885SLC29A1 7/4885 |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | NUDT1, HAVCR2, SLC28A1 | SLC28A1 3/4885SLC28A2 8/4885SLC29A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.